Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).
D007516:Adenoma, Islet Cell / Q000188:drug therapy; D001773:Blood Cells / Q000187:drug effects; D002051:Burkitt Lymphoma / Q000188:drug therapy; D002276:Carcinoid Tumor / Q000188:drug therapy / Q000652:urine; D002330:Carmustine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007082:Ileum; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000652:urine; D007668:Kidney / Q000187:drug effects; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013311:Streptozocin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000652:urine
D006897:Hydroxyindoleacetic Acid; D013311:Streptozocin; D002330:Carmustine